US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Drugs Made In America Acquisition Corp

10.76

+0.02000.19%

Post-market: 10.75-0.0100-0.09%16:00 EDT

Volume:15.14K

Turnover:162.56K

Market Cap:261.22M

PE:58.26

High:10.76

Open:10.75

Low:10.74

Close:10.74

52wk High:10.76

52wk Low:10.23

Shares:24.28M

Float Shares:19.69M

Volume Ratio:0.67

T/O Rate:0.08%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.1847

EPS(LYR):0.1878

ROE:--

ROA:-1.46%

PB:1.16

PE(LYR):57.31

Loading ...

Overview Company News Filings

Drugs Made in America Acquisition II FY26 Q2 Net Income Turns to Profit at $4.4 Million

Drugs Made in America Acquisition II swings to Q1 FY26 net income of $4.34 million

Drugs Made In America Acquisition agrees to merge with Power Analytics Global in $1 billion deal

Drugs Made In America Acquisition held shareholder meeting on extension amendment proposal

Drugs Made In America Acquisition sets CEO pay at $4,500 monthly plus 250,000 shares

Drugs Made in America Acquisition II posts FY25 net income of $4.2 million

Drugs Made in America Acquisition Corp Says Deal Anticipated to Value Power Analytics Global Corp at $1.0 Bln - SEC Filing

THOMSON REUTERS

Drugs Made In America Acquisition signs LOI to merge with Power Analytics Global at $1 billion valuation

Drugs Made in America Acquisition II issues $1.4 million convertible notes financing deal

Drugs Made in America Acquisition II delays annual report filing, targets April 15 deadline

Drugs Made In America Acquisition Corp. announced an extraordinary general meeting

Drugs Made In America Acquisition issued $100,000 interim convertible note to BV Advisory Partners; financing grows toward contemplated $500,000 total

Drugs Made in America Acquisition II Corp. signs USD 150,000 unsecured convertible bridge note with Alpha Multi Family Office

Drugs Made In America Acquisition Corp. Confirms $241.3 Million in Trust Account

Drugs Made In America Acquisition names Roger Bendelac CEO after Lynn Stockwell resigns

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/DMAA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DMAA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DMAA\",,,,,undefined,":{"symbol":"DMAA","market":"US","secType":"STK","nameCN":"Drugs Made In America Acquisition Corp","latestPrice":10.76,"timestamp":1787688000000,"preClose":10.74,"halted":0,"volume":15135,"hourTrading":{"tag":"盘后","latestPrice":10.75,"preClose":10.76,"latestTime":"16:00 EDT","volume":10,"amount":107.5,"timestamp":1787688001146,"change":-0.01,"changeRate":-0.000929,"amplitude":0},"delay":0,"changeRate":0.0018621973929236102,"floatShares":19688100,"shares":24276900,"eps":0.184691,"marketStatus":"Post-Mkt","change":0.02,"latestTime":"08-25 19:56:32 EDT","open":10.75,"high":10.76,"low":10.74,"amount":162555,"amplitude":0.001862,"askPrice":11.67,"askSize":100,"bidPrice":9.84,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.184691,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":10.74,"preHourTrading":{"tag":"盘前","latestPrice":10.7403,"preClose":10.74,"latestTime":"08:51 EDT","volume":4809,"amount":51552.605034,"timestamp":1787662304646,"change":0.0003,"changeRate":0.000028,"amplitude":0.00189},"postHourTrading":{"tag":"盘后","latestPrice":10.75,"preClose":10.76,"latestTime":"16:00 EDT","volume":10,"amount":107.5,"timestamp":1787688001146,"change":-0.01,"changeRate":-0.000929,"amplitude":0},"volumeRatio":0.666083},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DMAA\",,,,,undefined,":{"symbol":"DMAA","floatShares":19688100,"roa":"-1.46%","roe":"--","lyrEps":0.187761,"volumeRatio":0.666083,"shares":24276900,"dividePrice":0,"high":10.76,"amplitude":0.001862,"preClose":10.74,"low":10.74,"week52Low":10.23,"pbRate":"1.16","week52High":10.76,"institutionHeld":0,"latestPrice":10.76,"eps":0.184691,"divideRate":0,"volume":15135,"delay":0,"ttmEps":0.184691,"open":10.75,"prevYearClose":10.3742,"prevWeekClose":10.75,"prevMonthClose":10.71,"prevQuarterClose":10.65,"fiveDayClose":10.72,"twentyDayClose":10.71,"sixtyDayClose":10.61},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DMAA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-14","symbol":"DMAA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786680000000,"reportTimeType":"post","actualEps":null},{"date":"2026-05-14","symbol":"DMAA","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1778788800000,"name":null,"time":"Post-Mkt","dateTimestamp":1778731200000,"actualEps":null},{"market":"US","date":"2026-04-15","symbol":"DMAA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1776225600000,"reportTimeType":"post","actualEps":null},{"date":"2025-11-18","symbol":"DMAA","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1763499600000,"name":null,"time":"Post-Mkt","dateTimestamp":1763442000000,"actualEps":null},{"market":"US","date":"2025-08-14","symbol":"DMAA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DMAA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DMAA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DMAA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DMAA","date":"2026-08-24","current":58.259471,"percent":0.531328,"low":-5272.922078,"twenty":-716.569065,"median":-428.127254,"eighty":63.738934,"high":64.846367,"avg":-356.99751,"sd":512.036765,"marketCap":260976814},"quantilePoints":[{"date":"2025-01-10","current":-608.075079,"twenty":-608.075079,"median":-608.075079,"eighty":-608.075079,"marketCap":291714290},{"date":"2025-01-24","current":-5272.922078,"twenty":-1541.044479,"median":-608.075079,"eighty":-608.075079,"marketCap":2529600000},{"date":"2025-01-31","current":-425.873505,"twenty":-1541.044479,"median":-608.075079,"eighty":-425.745934,"marketCap":204306000},{"date":"2025-02-07","current":-426.936594,"twenty":-608.075079,"median":-426.511358,"eighty":-426.043599,"marketCap":204816000},{"date":"2025-02-14","current":-428.637537,"twenty":-608.075079,"median":-427.4894,"eighty":-426.086123,"marketCap":205632000},{"date":"2025-02-21","current":-429.488008,"twenty":-608.075079,"median":-428.127254,"eighty":-426.213694,"marketCap":206040000},{"date":"2025-02-28","current":-695.318062,"twenty":-642.693308,"median":-428.637537,"eighty":-426.426311,"marketCap":333567715},{"date":"2025-03-07","current":-697.410294,"twenty":-694.899616,"median":-429.062772,"eighty":-426.511358,"marketCap":334571430},{"date":"2025-03-14","current":-696.712883,"twenty":-696.294437,"median":-608.075079,"eighty":-426.7665,"marketCap":334236858},{"date":"2025-03-21","current":-698.805113,"twenty":-697.410294,"median":-608.075079,"eighty":-426.936594,"marketCap":335240572},{"date":"2025-03-28","current":-700.199934,"twenty":-697.689258,"median":-694.620652,"eighty":-427.446877,"marketCap":335909715},{"date":"2025-04-04","current":-700.058307,"twenty":-699.084077,"median":-694.969357,"eighty":-427.94015,"marketCap":335841772},{"date":"2025-04-11","current":-700.756969,"twenty":-700.114958,"median":-695.666767,"eighty":-428.144263,"marketCap":336176944},{"date":"2025-04-17","current":-700.756969,"twenty":-700.534155,"median":-696.712883,"eighty":-428.217404,"marketCap":336176944},{"date":"2025-04-25","current":-702.852952,"twenty":-700.756969,"median":-697.061588,"eighty":-428.39005,"marketCap":337182458},{"date":"2025-05-02","current":-704.250274,"twenty":-701.315898,"median":-697.410294,"eighty":-428.637537,"marketCap":337852801},{"date":"2025-05-09","current":-706.346256,"twenty":-702.154292,"median":-697.758998,"eighty":-428.637537,"marketCap":338858315},{"date":"2025-05-16","current":-706.695588,"twenty":-703.691345,"median":-698.805113,"eighty":-428.977725,"marketCap":339025901},{"date":"2025-05-23","current":-707.743579,"twenty":-704.948934,"median":-699.780416,"eighty":-429.743149,"marketCap":339528658},{"date":"2025-05-30","current":-708.09291,"twenty":-705.647596,"median":-700.058307,"eighty":-465.715705,"marketCap":339696244},{"date":"2025-06-06","current":-709.839561,"twenty":-706.346256,"median":-700.199934,"eighty":-608.075079,"marketCap":340534172},{"date":"2025-06-13","current":-710.538223,"twenty":-706.975053,"median":-700.756969,"eighty":-608.075079,"marketCap":340869344},{"date":"2025-06-20","current":-711.935546,"twenty":-707.743579,"median":-700.756969,"eighty":-608.075079,"marketCap":341539687},{"date":"2025-06-27","current":-711.236883,"twenty":-707.743579,"median":-700.756969,"eighty":-608.075079,"marketCap":341204515},{"date":"2025-07-03","current":-711.935546,"twenty":-708.861436,"median":-701.106301,"eighty":-677.311537,"marketCap":341539687},{"date":"2025-07-11","current":-713.332868,"twenty":-709.979293,"median":-701.738587,"eighty":-694.620652,"marketCap":342210030},{"date":"2025-07-18","current":-714.730188,"twenty":-710.95742,"median":-702.154292,"eighty":-694.620652,"marketCap":342880372},{"date":"2025-07-25","current":-716.826172,"twenty":-711.236883,"median":-702.852952,"eighty":-694.620652,"marketCap":343885887},{"date":"2025-08-01","current":-717.524833,"twenty":-711.935546,"median":-704.250274,"eighty":-695.17858,"marketCap":344221058},{"date":"2025-08-08","current":-717.524833,"twenty":-712.005412,"median":-704.948934,"eighty":-695.318062,"marketCap":344221058},{"date":"2025-08-15","current":-718.223495,"twenty":-713.332868,"median":-705.647596,"eighty":-695.597026,"marketCap":344556230},{"date":"2025-08-22","current":-717.524833,"twenty":-714.17126,"median":-706.342764,"eighty":-695.945732,"marketCap":344221058},{"date":"2025-08-29","current":-716.365056,"twenty":-714.86992,"median":-706.346256,"eighty":-696.573401,"marketCap":343664674},{"date":"2025-09-05","current":-716.826172,"twenty":-716.222528,"median":-706.695588,"eighty":-696.712883,"marketCap":343885887},{"date":"2025-09-12","current":-716.12751,"twenty":-716.48802,"median":-707.044919,"eighty":-696.712883,"marketCap":343550715},{"date":"2025-09-19","current":-718.223495,"twenty":-716.826172,"median":-707.743579,"eighty":-697.13133,"marketCap":344556230},{"date":"2025-09-26","current":-718.132667,"twenty":-716.826172,"median":-707.743579,"eighty":-697.410294,"marketCap":344512657},{"date":"2025-10-03","current":-717.524833,"twenty":-716.826172,"median":-708.09291,"eighty":-697.410294,"marketCap":344221058},{"date":"2025-10-10","current":-718.223495,"twenty":-717.52064,"median":-708.966236,"eighty":-697.410294,"marketCap":344556230},{"date":"2025-10-17","current":-720.319477,"twenty":-717.524833,"median":-709.839561,"eighty":-697.410294,"marketCap":345561744},{"date":"2025-10-24","current":-720.668808,"twenty":-717.524833,"median":-710.538223,"eighty":-697.828739,"marketCap":345729330},{"date":"2025-10-31","current":-721.018137,"twenty":-717.524833,"median":-710.887554,"eighty":-698.526149,"marketCap":345896915},{"date":"2025-11-07","current":-720.494143,"twenty":-717.524833,"median":-711.236883,"eighty":-698.805113,"marketCap":345645537},{"date":"2025-11-14","current":-721.018137,"twenty":-718.219302,"median":-711.236883,"eighty":-698.805113,"marketCap":345896915},{"date":"2025-11-21","current":63.492837,"twenty":-718.223495,"median":-711.236883,"eighty":-698.805113,"marketCap":345896915},{"date":"2025-11-28","current":63.554362,"twenty":-718.223495,"median":-711.236883,"eighty":-697.410294,"marketCap":346232087},{"date":"2025-12-05","current":63.554362,"twenty":-718.2207,"median":-711.236883,"eighty":-696.991847,"marketCap":346232087},{"date":"2025-12-12","current":63.738934,"twenty":-718.182971,"median":-710.538223,"eighty":-695.806249,"marketCap":347237601},{"date":"2025-12-19","current":63.738934,"twenty":-717.889533,"median":-709.839561,"eighty":-694.620652,"marketCap":347237601},{"date":"2025-12-26","current":63.800458,"twenty":-717.524833,"median":-709.839561,"eighty":-625.384194,"marketCap":347572772},{"date":"2026-01-02","current":63.826298,"twenty":-717.524833,"median":-708.79157,"eighty":-608.075079,"marketCap":347713544},{"date":"2026-01-09","current":63.861982,"twenty":-717.524833,"median":-707.918244,"eighty":-428.637537,"marketCap":347907944},{"date":"2026-01-16","current":63.98503,"twenty":-717.524833,"median":-707.743579,"eighty":-428.042207,"marketCap":348578287},{"date":"2026-01-23","current":64.231126,"twenty":-717.524833,"median":-707.743579,"eighty":-426.851547,"marketCap":349918972},{"date":"2026-01-30","current":64.231126,"twenty":-717.524833,"median":-707.044919,"eighty":-426.086123,"marketCap":349918972},{"date":"2026-02-06","current":64.169602,"twenty":-717.524833,"median":-706.695588,"eighty":-327.489953,"marketCap":349583801},{"date":"2026-02-13","current":64.200364,"twenty":-717.524833,"median":-706.346256,"eighty":63.554362,"marketCap":349751387},{"date":"2026-02-20","current":64.169602,"twenty":-717.524833,"median":-706.342764,"eighty":63.554608,"marketCap":349583801},{"date":"2026-02-27","current":64.477223,"twenty":-717.524833,"median":-705.647596,"eighty":63.67741,"marketCap":351259658},{"date":"2026-03-06","current":64.538747,"twenty":-717.524833,"median":-704.948934,"eighty":63.738934,"marketCap":351594830},{"date":"2026-03-13","current":64.415699,"twenty":-717.524833,"median":-704.250274,"eighty":63.738934,"marketCap":350924487},{"date":"2026-03-20","current":64.415699,"twenty":-717.524833,"median":-702.852952,"eighty":63.76908,"marketCap":350924487},{"date":"2026-03-27","current":64.661795,"twenty":-717.524833,"median":-702.154292,"eighty":63.800458,"marketCap":352265172},{"date":"2026-04-02","current":64.600271,"twenty":-717.524833,"median":-702.021545,"eighty":63.826298,"marketCap":351930001},{"date":"2026-04-10","current":64.692557,"twenty":-717.524833,"median":-701.280966,"eighty":63.861982,"marketCap":352432758},{"date":"2026-04-17","current":59.466742,"twenty":-717.524833,"median":-700.756969,"eighty":63.972725,"marketCap":353270687},{"date":"2026-04-24","current":59.822154,"twenty":-717.524833,"median":-700.756969,"eighty":63.917354,"marketCap":355382058},{"date":"2026-05-01","current":59.764829,"twenty":-717.522038,"median":-700.756969,"eighty":63.861982,"marketCap":355041515},{"date":"2026-05-08","current":60.162126,"twenty":-717.403265,"median":-700.199934,"eighty":63.861982,"marketCap":357401715},{"date":"2026-05-15","current":60.10537,"twenty":-717.209037,"median":-700.058307,"eighty":63.861982,"marketCap":357064544},{"date":"2026-05-22","current":53.691662,"twenty":-717.035769,"median":-699.153818,"eighty":63.861982,"marketCap":357401715},{"date":"2026-05-29","current":53.691662,"twenty":-716.826172,"median":-698.805113,"eighty":63.854845,"marketCap":357401715},{"date":"2026-06-05","current":53.742314,"twenty":-716.826172,"median":-697.410294,"eighty":63.826298,"marketCap":357738887},{"date":"2026-06-12","current":53.742314,"twenty":-716.826172,"median":-697.410294,"eighty":63.82113,"marketCap":357738887},{"date":"2026-06-18","current":53.792967,"twenty":-716.826172,"median":-697.061588,"eighty":63.800458,"marketCap":358076058},{"date":"2026-06-26","current":53.894272,"twenty":-716.826172,"median":-696.712883,"eighty":63.800458,"marketCap":358750401},{"date":"2026-07-02","current":53.894272,"twenty":-716.826172,"median":-695.666767,"eighty":63.800458,"marketCap":358750401},{"date":"2026-07-10","current":53.970251,"twenty":-716.826172,"median":-694.969357,"eighty":63.800458,"marketCap":359256158},{"date":"2026-07-17","current":53.944924,"twenty":-716.826172,"median":-694.620652,"eighty":63.800458,"marketCap":359087572},{"date":"2026-07-24","current":54.147534,"twenty":-716.826172,"median":-608.075079,"eighty":63.800458,"marketCap":360436258},{"date":"2026-07-31","current":54.24884,"twenty":-716.826172,"median":-608.075079,"eighty":63.76908,"marketCap":361110601},{"date":"2026-08-07","current":54.24884,"twenty":-716.826172,"median":-429.488008,"eighty":63.742625,"marketCap":361110601},{"date":"2026-08-14","current":54.24884,"twenty":-716.826172,"median":-428.637537,"eighty":63.738934,"marketCap":361110601},{"date":"2026-08-21","current":59.331199,"twenty":-716.633342,"median":-428.212301,"eighty":63.738934,"marketCap":361616358},{"date":"2026-08-24","current":42.819045,"twenty":-716.569065,"median":-428.127254,"eighty":63.738934,"marketCap":260976814}],"updateTime":1787702188001},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DMAA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659129884","title":"Drugs Made in America Acquisition II FY26 Q2 Net Income Turns to Profit at $4.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659129884","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659129884?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:11","pubTimestamp":1786738284,"startTime":"0","endTime":"0","summary":"Drugs Made in America Acquisition II FY26 Q2 net income turns to profit at $4.4 millionDrugs Made in America Acquisition II posted net income of $4.4 million for the quarter ended June 30, 2026.Genera","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL764nkh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAA","DMIIU","DMII"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635725101","title":"Drugs Made in America Acquisition II swings to Q1 FY26 net income of $4.34 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635725101","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635725101?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:22","pubTimestamp":1778790161,"startTime":"0","endTime":"0","summary":"Drugs Made in America Acquisition II posted net income of USD 4.34 million for the quarter ended March 31, 2026, swinging from a net loss of USD 59,327 a year earlier.Interest earned on cash and investments held in the trust account totaled USD 4.44 million, while general and administrative costs were USD 132,030.Cash on hand was USD 347,720 at March 31, 2026, up from USD 223 at Dec. 31, 2025.Management said substantial doubt exists about its ability to continue as a going concern within one year, tied to completing an initial business combination within its 24-month window.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made in America Acquisition II Corp. published the original content used to generate this news brief via EDGAR","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDLcfh50g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMIIU","DMII","DMAA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633920824","title":"Drugs Made In America Acquisition agrees to merge with Power Analytics Global in $1 billion deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2633920824","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633920824?lang=en_us&edition=fundamental","pubTime":"2026-05-06 05:39","pubTimestamp":1778017188,"startTime":"0","endTime":"0","summary":"Drugs Made In America Acquisition Corp. signed a merger agreement on April 29, 2026, with Power Analytics Global Corp., an artificial intelligence, advanced analytics, and quantum-resistant security business.Transaction targets a $1 billion enterprise valuation for Power Analytics, subject to a valuation schedule tied to verified, signed revenue contracts delivered by closing.Agreement includes a $300 million floor valuation, below which parties can renegotiate or terminate.Post-close ownership expected to be about 90% for legacy Power Analytics shareholders, about 10% for existing DMAA shareholders, before any PIPE or other closing issuances.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made In America Acquisition Corp. publis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDLW2fnX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4200","BK4122","DMAA","SHRG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632640086","title":"Drugs Made In America Acquisition held shareholder meeting on extension amendment proposal","url":"https://stock-news.laohu8.com/highlight/detail?id=2632640086","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632640086?lang=en_us&edition=fundamental","pubTime":"2026-05-02 05:06","pubTimestamp":1777669571,"startTime":"0","endTime":"0","summary":"Drugs Made in America Acquisition Corp. held an extraordinary general meeting on April 27, 2026.Shareholders adopted a charter amendment to allow up to 12 one-month extensions of business-combination deadline from April 29, 2026 to April 29, 2027.Extension remains conditional on sponsor deposits of lesser of $300,000 or $0.04 per non-redeemed public share for each one-month extension period into trust account.Adjournment resolution was not presented, since sufficient votes were available to pass extension amendment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made In America Acquisition Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL5vWxx5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631531845","title":"Drugs Made In America Acquisition sets CEO pay at $4,500 monthly plus 250,000 shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2631531845","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631531845?lang=en_us&edition=fundamental","pubTime":"2026-04-29 05:09","pubTimestamp":1777410567,"startTime":"0","endTime":"0","summary":"Drugs Made In America Acquisition updated engagement terms for CFO Saleem Elmasri on April 22, 2026, keeping monthly compensation at $3,500.Outstanding amounts under Elmasri’s services arrangement remain unpaid, continuing to accrue as company obligations.Elmasri became entitled to 175,000 ordinary shares, earned upon execution of a definitive agreement.Separate April 22, 2026 agreement set CEO Roger E. Bendelac compensation at $4,500 per month, with $2,500 payable currently.Bendelac also became entitled to 250,000 ordinary shares, to be issued at closing of initial business combination within 10 days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made In America Acquisition Corp. published the original content used to generate ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL9fBRYJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627923779","title":"Drugs Made in America Acquisition II posts FY25 net income of $4.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2627923779","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627923779?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:11","pubTimestamp":1776283882,"startTime":"0","endTime":"0","summary":"Drugs Made in America Acquisition II posted net income of USD 4.2 million for fiscal 2025, driven by USD 4.9 million of interest earned on cash and investments held in the trust account.Revenue was not reported, as the SPAC had not generated operating revenues to date.General and administrative costs totaled USD 488,385, while a USD 812,113 provision for credit losses reflected a full reserve against amounts due from the sponsor.Management said conditions raised substantial doubt about its ability to continue as a going concern within one year after the financial statements are issued.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made in America Acquisition II Corp. published the original content used to generate this news brie","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL3vSnT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMIIU","DMAA","DMII"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625448429","title":"Drugs Made in America Acquisition Corp Says Deal Anticipated to Value Power Analytics Global Corp at $1.0 Bln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2625448429","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625448429?lang=en_us&edition=fundamental","pubTime":"2026-04-08 21:03","pubTimestamp":1775653401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nFWN40R0LJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DMAA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625941027","title":"Drugs Made In America Acquisition signs LOI to merge with Power Analytics Global at $1 billion valuation","url":"https://stock-news.laohu8.com/highlight/detail?id=2625941027","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625941027?lang=en_us&edition=fundamental","pubTime":"2026-04-08 21:01","pubTimestamp":1775653313,"startTime":"0","endTime":"0","summary":"Drugs Made in America Acquisition entered a letter of intent on April 7, 2026 to pursue a de-SPAC deal with Power Analytics Global.Proposed transaction would take Power Analytics Global public.Target valuation expected at about $1 billion, subject to due diligence and adjustments for capital structure, net debt, working capital, and market conditions.Parties expect to negotiate and sign a definitive business combination agreement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made In America Acquisition Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 08, 2026, and is so","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDLLFmq6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624968664","title":"Drugs Made in America Acquisition II issues $1.4 million convertible notes financing deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2624968664","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624968664?lang=en_us&edition=fundamental","pubTime":"2026-04-04 04:34","pubTimestamp":1775248467,"startTime":"0","endTime":"0","summary":"Drugs Made in America Acquisition II entered into a definitive investment agreement on March 24, 2026 for a contemplated convertible notes financing.Company issued an interim convertible note of USD 0.3 million on March 30, 2026 to Alpha Multi Family Office.Note matures nine months from issuance, carries no interest.Investor can convert principal at business combination into shares at 35% discount to market price at conversion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made in America Acquisition II Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 03, 2026, and is so","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDLWvCKf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMIIU","DMII","DMAA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624549999","title":"Drugs Made in America Acquisition II delays annual report filing, targets April 15 deadline","url":"https://stock-news.laohu8.com/highlight/detail?id=2624549999","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624549999?lang=en_us&edition=fundamental","pubTime":"2026-04-02 04:06","pubTimestamp":1775073978,"startTime":"0","endTime":"0","summary":"Drugs Made in America Acquisition II reported it will miss deadline for its Form 10-K for fiscal year ended Dec. 31, 2025.Delay was attributed to inability to compile all information needed for financial statements and related disclosures without unreasonable effort or expense.Filing indicated no anticipated significant change in results of operations versus prior-year period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made in America Acquisition II Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained there","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL5bnzTr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMII","DMIIU","DMAA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622036308","title":"Drugs Made In America Acquisition Corp. announced an extraordinary general meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2622036308","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622036308?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:58","pubTimestamp":1774645138,"startTime":"0","endTime":"0","summary":"Drugs Made In America Acquisition will hold an extraordinary general meeting in New York in April 2026.Shareholders will vote on a charter amendment to extend the deadline to complete a business combination from April 29, 2026 to a date in 2027, in up to one-month increments.A separate proposal will seek approval to adjourn the meeting to a later date if needed to continue soliciting votes on the extension.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made In America Acquisition Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 27, 2026, and is solely responsible for the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL6CzvlP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622870099","title":"Drugs Made In America Acquisition issued $100,000 interim convertible note to BV Advisory Partners; financing grows toward contemplated $500,000 total","url":"https://stock-news.laohu8.com/highlight/detail?id=2622870099","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622870099?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:08","pubTimestamp":1774642083,"startTime":"0","endTime":"0","summary":"Drugs Made In America Acquisition issued $100,000 interim convertible note to BV Advisory Partners; financing grows toward contemplated $500,000 total. The note matures six months after issuance unless earlier converted or credited toward a contemplated USD 500,000 financing under a separate investment agreement.Upon completion of an initial business combination, BV Advisory Partners may convert the outstanding principal into shares at a conversion price set at a 35% discount to the market price at conversion.Proceeds are intended for accounting and audit expenses and other business combination-related costs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made In America Acquisition Corp. published the original content used to ge","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDLbMsKSw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620803408","title":"Drugs Made in America Acquisition II Corp. signs USD 150,000 unsecured convertible bridge note with Alpha Multi Family Office","url":"https://stock-news.laohu8.com/highlight/detail?id=2620803408","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620803408?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:02","pubTimestamp":1773777749,"startTime":"0","endTime":"0","summary":"Drugs Made in America Acquisition II Corp. signs USD 150,000 unsecured convertible bridge note with Alpha Multi Family Office. Drugs Made in America Acquisition II issued an unsecured convertible bridge note to Alpha Multi Family Office with principal of 150,000. The note matures nine months after issuance and does not bear interest. Upon completion of the company’s initial business combination, the investor may convert the outstanding principal into shares at a 35% discount to the market price at conversion. Proceeds are intended for accounting and audit expenses related to the business combination.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made in America Acquisition II Corp. published the original content used to generate","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL7hhMTg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMII","DMIIU","DMAA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617925653","title":"Drugs Made In America Acquisition Corp. Confirms $241.3 Million in Trust Account","url":"https://stock-news.laohu8.com/highlight/detail?id=2617925653","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617925653?lang=en_us&edition=fundamental","pubTime":"2026-03-07 06:02","pubTimestamp":1772834530,"startTime":"0","endTime":"0","summary":"Drugs Made In America Acquisition Corp. issued a clarification stating that after learning of improper withdrawals from an affiliate’s working capital account, its board acted to confirm the issue did not affect the company’s trust account. The company said that as of March 6, 2026, approximately $241,292,436 remains in its trust account.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made In America Acquisition Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 06, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL9LyZs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617870639","title":"Drugs Made In America Acquisition names Roger Bendelac CEO after Lynn Stockwell resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2617870639","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617870639?lang=en_us&edition=fundamental","pubTime":"2026-03-06 23:15","pubTimestamp":1772810110,"startTime":"0","endTime":"0","summary":"Drugs Made In America Acquisition Corp. said CEO and Executive Chair Lynn Stockwell resigned and was removed from the board, effective Feb. 28, 2026. The company appointed Roger Bendelac as CEO effective the same date. Bendelac, 69, has more than 30 years of experience in investment banking and corporate advisory work.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made In America Acquisition Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 06, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL2Nkk3V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":15,"code":"91000000","status":"200"}]}}